Stay updated on Miransertib in Overgrowth Spectrum Clinical Trial
Sign up to get notified when there's something new on the Miransertib in Overgrowth Spectrum Clinical Trial page.

Latest updates to the Miransertib in Overgrowth Spectrum Clinical Trial page
- Check7 days agoChange DetectedAdded study site locations: Georgia, Illinois, Massachusetts, Ohio, Texas, Washington, New South Wales, Roma, and Barcelona (revision v3.3.3). Removed corresponding location entries for Georgia, Illinois, Massachusetts, Ohio, Texas, Washington, New South Wales, Roma, and Barcelona (revision v3.3.2).SummaryDifference0.9%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedThese additions and deletions describe how PubMed publications are automatically populated in the study record and report a revision version (Revision: v3.3.2). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check43 days agoChange DetectedRemoval of the lapse in government funding notice from the page; all study details and content remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check57 days agoChange DetectedNo significant additions or deletions were observed; the page content remains consistent with the MOSAIC study details and related information.SummaryDifference0.4%

- Check86 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference3%

- Check93 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update.SummaryDifference0.1%

Stay in the know with updates to Miransertib in Overgrowth Spectrum Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Miransertib in Overgrowth Spectrum Clinical Trial page.